Arachidonylcyclopropylamide: Difference between revisions
CSV import |
CSV import |
||
| Line 29: | Line 29: | ||
{{Pharmacology-stub}} | {{Pharmacology-stub}} | ||
{{No image}} | {{No image}} | ||
== Arachidonylcyclopropylamide == | |||
<gallery> | |||
File:Arachidonylcyclopropylamide.svg|Arachidonylcyclopropylamide | |||
</gallery> | |||
Revision as of 00:02, 25 February 2025
Arachidonylcyclopropylamide (ACPA) is a synthetic cannabinoid and a potent agonist of the CB1 receptor. It was developed in the late 20th century as part of research into cannabinoids and their effects on the human body.
Chemistry
Arachidonylcyclopropylamide is a fatty acid amide and is structurally similar to anandamide, a naturally occurring cannabinoid in the human body. It is a derivative of arachidonic acid, a polyunsaturated omega-6 fatty acid. The cyclopropyl group in ACPA is responsible for its affinity for the CB1 receptor.
Pharmacology
ACPA is a full agonist of the CB1 receptor, meaning it fully activates the receptor when it binds to it. This is in contrast to partial agonists, which only partially activate the receptor, and antagonists, which prevent the receptor from being activated. ACPA's affinity for the CB1 receptor is believed to be responsible for its psychoactive effects.
Effects
The effects of ACPA are similar to those of other cannabinoids, such as tetrahydrocannabinol (THC), the main psychoactive compound in cannabis. These effects can include relaxation, euphoria, altered perception, and increased appetite. However, as a synthetic cannabinoid, ACPA may have additional effects not seen with natural cannabinoids.
Research and Legal Status
Research into ACPA and other synthetic cannabinoids is ongoing, with a focus on understanding their potential therapeutic uses and risks. In many jurisdictions, ACPA is a controlled substance due to its psychoactive effects.
See Also
Arachidonylcyclopropylamide
-
Arachidonylcyclopropylamide
